Boehringer's Spiriva/Micardis remarkably grew up.

Published: 2005-08-10 06:56:00

Updated: 2005-08-10 06:56:00

Boehringer Ingelheim achieved 22% sales up during the first half of this year at 4.5 billion Euro dollars (5,700 billion won), thank to the new AIDS drug, Aptivus, a COPD therapeutic drug (Spririva) and a new anti-hypertension drug (Micardis). The operating incomes recorded 768 million Euro dolla...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK